Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loncastuximab tesirine + mosunetuzumab
- Development stage
- Unknown
- Lead developer
- ADC Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Loncastuximab tesirine + mosunetuzumab** is a combination of two targeted immunotherapies developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting CD19 on B cells, delivering a cytotoxic pyrrolobenzodiazepine (PBD) payload (tesirine) that crosslinks DNA and induces cell death. Mosunetuzumab is a bispecific T-cell engager monoclonal antibody that simultaneously binds CD20 on B-cells and CD3 on T-cells, redirecting T-cells to kill CD20+ malignant B cells. The combination is under clinical investigation (e.g., phase 2 LOTIS-7, NCT05672251) to assess safety and efficacy in R/R DLBCL, leveraging dual targeting of tumor antigens and immune cell engagement to enhance tumor control[1][5][6].
- Brand names
- Zynlonta + Lunsumio
- Other names
- loncastuximab tesirine-lpylmosunetuzumab-axgb
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on loncastuximab tesirine + mosunetuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loncastuximab tesirine + mosunetuzumab.